Pharmaceuticals
NUS researchers develop microneedle technology to accelerate diabetic wound healing
'Sponge-like' microneedle patches deliver bioactive ingredients and reduce inflammation in slow- and non-healing wounds SINGAPORE, March 26, 2025 /PRNewswire/ -- Diabetic wounds often lead to severe complications that can result in amputations. These chronic and non-healing wounds are marked by ...
2025-03-26 14:21
2480
Alphamab Oncology Reports Full Year 2024 Financial Results and Business Highlights
SUZHOU, China, March 26, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year endedDecember 31, 2024 and highlighted recent business progress. Financial Summary * For the year ended December 31, 2024, we recorded total revenue of RMB 640.08...
2025-03-26 11:08
2158
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2024
SHANGHAI, March 26, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines and vaccines, today announced its financial results for ...
2025-03-26 11:03
7663
Fosun Pharma Announces 2024 Annual Results
Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY SHANGHAI, March 25, 2025 /PRNewswire/ -- On March 25, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"or "the Group"; Stock Code: 600196.SH, 02196.HK), a leading global pharmaceutica...
2025-03-26 10:29
2856
CStone to Showcase Five Latest Research Achievements at AACR 2025
SUZHOU, China, March 25, 2025 /PRNewswire/ -- From April 25 to 30, 2025, the American Association for Cancer Research (AACR) Annual Meeting will take place inChicago. CStone will showcase its latest preclinical studies on five internally developed innovative candidates, including the trispecific ...
2025-03-26 08:15
2027
Glenmark Pharmaceuticals Launches Pioneering Nutrition Program to Fight Malnutrition in the Philippines
MANILA, Philippines, March 25, 2025 /PRNewswire/ -- Glenmark Pharmaceuticals Ltd. (Glenmark), a leading research-led, global pharmaceuticals company has partnered with, Health Futures Foundation, Inc. (HFI) and the Municipality of Malinao to launch a comprehensive initiative to improve nutrition ...
2025-03-25 20:12
2057
AccurEdit Therapeutics' LNP-based In Vivo Gene Editing Product ART001 Obtained Orphan Drug Designation from the FDA
CAMBRIDGE, Mass., March 25, 2025 /PRNewswire/ -- AccurEdit Therapeutics today announced that its innovativein vivo gene editing product, ART001, has obtained Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA). ART001, which utilizes lipid nanoparticle (LNP) technolog...
2025-03-25 19:00
1790
Rare loss-of-function variants in HECTD2 and AKAP11 confer a risk of bipolar disorder
Scientists at deCODE genetics, a subsidiary of Amgen, reveal today in Nature Genetics associations between rare loss-of-function variants in two genes and bipolar disorder. REYKJAVIK, Iceland, March 25, 2025 /PRNewswire/ -- Bipolar disorder is characterized by extreme mood swings, bouts of mania...
2025-03-25 18:00
2675
Exceptional Performance for Ureteral Stents: ICP DAS-BMP Reveals Latest TPU Materials at CMEF 2025
HSINCHU, March 25, 2025 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), a committedTaiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), is excited to announce its participation in CMEF (China International Medical Equipment Fair), held fromApril 8-11, 2025,...
2025-03-25 09:45
2364
Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY
SHANGHAI, March 24, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius' total revenue reached approximatelyRMB5.7244 billion, representing an increase of 6.1% YoY. The net profit reachedRMB820.5 million, a 50.3% YoY growth, with a net pr...
2025-03-24 23:09
3181
Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY
SHANGHAI, March 24, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius' total revenue reached approximatelyRMB5.7244 billion, representing an increase of 6.1% YoY. The net profit reachedRMB820.5 million, a 50.3% YoY growth, with a net pr...
2025-03-24 22:54
3473
WuXi XDC Achieved Another Remarkable Year with Extraordinary Business Performance and Financial Results for 2024
* Revenue increased by 90.8% YoY to RMB 4,052 million * Gross profit grew by 121.6% YoY to RMB 1,240 million, with its margin of 30.6%, a 4.3 percentage points increase compared to that of 2023 * Net profit surged by 277.2% YoY to RMB 1,070 million, with its margin of 26.4%, a 13.0 percentag...
2025-03-24 22:45
3257
Sermonix and Regor Announce Strategic Collaboration to Optimize Regor's Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics
Partnership aims to develop efficacious and well-tolerated treatments for advanced metastatic breast cancer COLUMBUS, Ohio, and CAMBRIDGE, Mass., March 24, 2025 /PRNewswire/ -- Sermonix Pharmaceuticals, a privately held biopharmaceutical company developing innovative therapeutics to specifically...
2025-03-24 22:30
1799
Sungen Biomedical's world-first new drug SGC001 monoclonal antibody receives FDA fast track approval
NEW YORK, March 24, 2025 /PRNewswire/ -- On March 17, 2025, US time, the world's first acute myocardial infarction (AMI) antibody drug, SGC001, developed by Sungen Biomedical—an innovative biopharmaceutical company incubated by Beijing Hotgen Biotech Co., Ltd. (SH.688068)—received Fast Track Des...
2025-03-24 21:00
1600
Ractigen's RAG-01 Shows Promising Early Complete Responses in Phase I NMIBC Trial, Data Presented at EAU 2025
NANTONG, China and MELBOURNE, Australia, March 24, 2025 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics, today announced the presentation of positive preliminary data from its ongoing Phase I clinical trial of ...
2025-03-24 20:30
1901
SineuGene Therapeutics Announces FDA IND Clearance for SNUG01, a First-in-Class TRIM72-Targeted Gene Therapy for ALS
BEIJING, March 24, 2025 /PRNewswire/ -- SineuGene Therapeutics Co., Ltd. ("SineuGene"), a clinical-stage biotech company pioneering innovative therapies for neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) appl...
2025-03-24 20:00
3258
GSK's Omjjara (momelotinib) approved in Singapore as the first treatment indicated for myelofibrosis patients with anaemia
* Approval is for use in myelofibrosis patients with moderate to severe anaemia who are JAK-naive or previously treated with ruxolitinib * Nearly all myelofibrosis patients globally are estimated to develop anaemia over the course of the disease, and over 30% will discontinue treatment due to ...
2025-03-24 10:00
2040
ArkBio Announces the Completion of Phase III Clinical Study for AK0901 in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in China
SHANGHAI, March 24, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the successful completion of the Phase III clinical study of AK0901, a novel drug for the treatment of attention deficit hyperactivity disorder (ADHD). This milestone represents a substant...
2025-03-24 09:00
2866
CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer
SUZHOU, China, March 23, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation application to the European Medicines Agency (EMA) for sugemalimab. T...
2025-03-24 08:15
2242
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer
SAN FRANCISCO and SUZHOU, China, March 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmun...
2025-03-24 08:00
2624
Week's Top Stories
Most Reposted
Amorepacific Showcases Innovative Technologies at CES 2026
[Picked up by 291 media titles]
2026-01-05 12:14
Novo Nordisk International Operations Commits to Veeva Vault CRM
[Picked up by 288 media titles]
2026-01-08 09:05Radisson Hotel Group Revives Bangkok Icon with Opening of Radisson Hotel Chateau de Bangkok
[Picked up by 283 media titles]
2026-01-06 10:45
Courtyard by Marriott Phuket, Patong Beach Resort: The Ultimate Family-Friendly Destination in 2026
[Picked up by 283 media titles]
2026-01-08 12:01
Panduit Announces Key Executive Appointments to Support Strategic Growth and Innovation
[Picked up by 282 media titles]
2026-01-07 10:00
Most Read
Domestic GPU Leader Biren Technology Listed on Hong Kong Stock Exchange
2026-01-02 17:41
7886
The Greatest Meeting The Greatest: Roborock joins hands with Real Madrid in strategic partnership with innovation at the core
2026-01-02 19:00
7436
